Diabetes mellitus is a frequent comorbidity in patients with community-acquired pneumonia. Adding adjunct prednisone to the standard treatment of pneumonia beneficially quickens resolution of illness and shortens length of hospital stay. However, the hyperglycaemic effects of prednisone raise concern about its use in diabetic individuals. In this issue, Popovic, Blum et al report the effects of prednisone on outcome in a preplanned subanalysis of a randomised, placebo-controlled, multicentre trial including 138 patients with diabetes. Prednisone did not have negative effects on outcome, but led to a shorter resolution of illness (HR for time to clinical stability 1.65 [95%CI 1.16, 2.35]; p = 0.007). There was no evidence for effect modification by diabetes upon interaction analysis (p = 0.44). Although adjunct prednisone was associated with a higher risk for hyperglycaemia, this did not worsen clinical outcomes. These results have immediate clinical implications, suggesting that corticosteroids, such as prednisone, should be considered an appropriate adjunct treatment for pneumonia in diabetic patients. This article is the subject of a commentary in this issue by N. Wah Cheung.
Oxidative stress, or the excessive accumulation of reactive oxygen species (ROS), such as superoxide or H 2 O 2 , has been implicated in the development of insulin resistance, hepatic steatosis and non-alcoholic steatohepatitis (NASH) in obesity. Moreover, H 2 O 2 is generated as part of normal signal transduction and may act as a second messenger, promoting signalling by hormones, including insulin. The precise type of ROS contributing to disease progression, and the cellular and subcellular origins of these ROS, remain unclear. In this issue, Merry, Tran et al generate mice lacking hepatic glutathione peroxide 1 (GPX1). This antioxidant enzyme converts H 2 O 2 to water. They report that GPX1-deficiency increases H 2 O 2 in hepatocytes, promotes insulin sensitivity and attenuates the development of NASH and hepatic fibrosis. These findings warrant reconsideration of the contributions of ROS to hepatic pathophysiology in obesity and suggest that increases in hepatocyte H 2 O 2 may be beneficial in attenuating disease progression. This article is the subject of a commentary in this issue by Haas and Staels.
The suppression of hepatic glucose production improves metabolism and insulin sensitivity in subcutaneous adipose tissue in mice Sylvie Casteras, Aya Abdul-Wahed, Maud Soty, Fanny Vulin, Hervé Guillou, Mélanie Campana, Hervé Le Stunff, Luciano Pirola, Fabienne Rajas, Gilles Mithieux, Amandine Gautier-Stein Steatosis is often associated with insulin resistance, but surprisingly, in some circumstances, it is also associated with improved insulin sensitivity. In this issue, Casteras et al report that shifting hepatic metabolism from glucose to lipid production improves adipose tissue catabolism. The absence of glucose production and the stimulation of lipogenesis lead to the release of the hepatokine fibroblast growth factor 21 (FGF21), and to changes in hepatic fatty acid profile. More precisely, the amount of the monounsaturated fatty acid, oleate, increases while the amount of the saturated fatty acid, palmitate, decreases. While FGF21 stimulates energy expenditure and decreases body weight, oleate improves insulin sensitivity in the inguinal white adipose tissue. These findings highlight the role of the liver in the control of whole body metabolism and suggest that hepatic glucose production controls the development of peripheral insulin resistance in steatotic patients. Fat breakdown via lipolysis generates signalling molecules that control many biological functions in different tissues. Lipolysis also contributes to energy production by releasing fatty acids, which may subsequently undergo oxidation. Adipose triglyceride lipase (ATGL), an enzyme which catalyses the first committed step of lipolysis, regulates fat and carbohydrate metabolism and also glucose-stimulated insulin secretion (GSIS). In this issue, Attané et al report that pancreatic beta cell ATGL and lipolysis control whole body energy homeostasis, weight gain, energy expenditure and insulin sensitivity, all via regulation of GSIS from beta cells. They demonstrate that the reduction of beta cell lipolysis upon ATGL deletion dampens GSIS and enhances adipose tissue metabolism, thermogenesis and insulin sensitivity. These results indicate that insulin hypersecretion in response to nutrient excess drives obesity, insulin resistance and hyperglycaemia. Thus, the authors raise the need to question the validity of high doses of insulin therapy for obese individuals with type 2 diabetes. This article is the subject of a commentary in this issue by Hindrik Mulder.
Beta cell function and ongoing autoimmunity in longstanding, childhood onset type 1 diabetes Contrary to previous assumptions, some individuals with established type 1 diabetes retain limited insulin secretion. However, these findings are based on research in diabetic patients without islet autoantibody data at diagnosis. In this issue, Williams, Long et al report data from a sub-study of the Bart's Oxford family study, selecting participants who were islet autoantibody positive at diagnosis. Approximately two decades after diagnosis, one third of cases continued to secrete detectable levels of C-peptide, although this rarely occurred in children diagnosed under the age of 5 years. Additionally, two thirds of participants remained positive for at least one autoantibody. Of these, antibodies to islet antigen-2 were more common than those to GAD, while zinc transporter 8 antibodies rarely persisted. C-peptide level and autoantibodies were not associated at diagnosis or after disease onset. In summary, endogenous insulin secretion may continue for years after diagnosis in individuals with ongoing islet autoimmunity, suggesting that some beta cells may be protected from autoimmune attack.
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